Modelling study using 5-year antibody data from a phase 3 trial of two-dose inactivated EV71 vaccine in infants and young children: estimated protective efficacy was 80.19% at month 1, declining to 72.57% at year 20 under current conditions in China.
RCT
Ma et al. Long-term protection of an inactivated enterovirus type 71 vaccine against hand, foot, and mouth diseases in children: a modelling study